Oncology

An alliance between Clínica Medilaser and the Instituto Médico Oncológico has consolidated an integrated program to treat central nervous system tumors in southern Colombia. The service, led by neurosurgeon Silvia Quintero, serves patients from several regions from its Neiva site.

5. mai 2026 Rapportert av AI

One month after the nationwide oncology sanitary alert took effect, Health Minister May Chomali led the signing of a decree transferring $154 billion from the Ministry of Hacienda to the Ministry of Health (Minsal). The funds will exclusively support the Oncology Alert Plan, enhancing public health services' capacity to resolve oncology waiting lists affecting thousands of patients.

Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.

22. november 2025 Rapportert av AI

Oncologist Paulo Hoff warned that excessive sun exposure is the most common cause of cancer, particularly non-melanoma skin cancer. In a course on CasaFolha, he emphasizes the importance of prevention and early diagnosis to boost cure rates. Hoff recommends avoiding the sun between 10am and 2pm and using sunscreen.

A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.

3. oktober 2025 Rapportert av AI

Researchers at Spain's National Cancer Research Centre (CNIO) have developed a comprehensive catalog of mutational 'scars' in DNA caused by cancer. This breakthrough, published in Nature, could help bypass resistances to treatments like PARP inhibitors. The study analyzes thousands of tumor samples to identify key genetic patterns.